经中国证券监督管理委员会《关于核准上海现代制药股份有限公司非公开发 行股票的批复》（证监许可〔2022〕3065 号）核准，并经上海证券交易所同意， 公司于 2022 年 12 月 29 日以非公开发行股票的方式向中国医药集团有限公司发 行了人民币普通股股票 145,102,781 股，每股价格为每股人民币 8.27 元。本次非 公开发行股票募集资金总额为人民币 1,199,999,998.87 元，扣除与发行有关的费 用 13,084,635.86 元后，募集资金净额为 1,186,915,363.01 元。大华会计师事务所 （特殊普通合伙）于 2022 年 12 月 30 日对上海现代制药股份有限公司 2022 年度 非公开发行股票的资金到位情况进行了审验，并出具了"大华验字〔2022〕000955 号"验资报告。 中信证券股份有限公司 关于上海现代制药股份有限公司 2024年度持续督导报告书 | 上市公司：上海现代制药股份有限公司（以下简称"国药现代"、"公司"） | | | --- | --- | | 保荐人名称：中信证券股份有限公司（以下简称"中信证券"或"保荐人"） | | | 保荐代表人姓名：丁 ...

中信证券股份有限公司关于 上海现代制药股份有限公司非公开发行股票持续督导 保荐总结报告书 保荐人编号：Z20374000 申报时间：2025 年 4 月 | 公司名称 | 上海现代制药股份有限公司 | | --- | --- | | 英文名称 | Shanghai Shyndec Pharmaceutical Co., Ltd. | | 统一社会信用代码 | 91310000630459924R | | 注册资本 | 元人民币 1,341,172,692 | | 法定代表人 | 许继辉 | | 成立日期 | 1996-11-27 | | 上市日期 | 2004-6-16 | | 注册地址 | 上海市浦东新区建陆路 378 号 | | 办公地址 | 上海市浦东新区建陆路 378 号 | | 证券代码 | 600420.SH | | 证券简称 | 国药现代 | 一、发行人基本情况 二、本次发行情况概述 经中国证券监督管理委员会《关于核准上海现代制药股份有限公司非公开发 行股票的批复》（证监许可〔2022〕3065 号）核准，并经上海证券交易所同意， 公司于 2022 年 12 月 29 日以非公开发行股票的方式向 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-031 上海现代制药股份有限公司 关于全资孙公司获得化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产企业：江苏威奇达药业有限公司 企业地址：南通市海门区临江镇临江大道 1 号 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 近日，上海现代制药股份有限公司（以下简称公司）全资孙公司江苏威奇达 药业有限公司(以下简称国药江苏威奇达)收到国家药品监督管理局核准签发的 《化学原料药上市申请批准通知书》，批准原料药枸橼酸托法替布上市申请，现 将相关情况公告如下： 一、化学原料药基本信息 化学原料药名称：枸橼酸托法替布 登记号：Y20230000702 通知书编号：2025YS00284 化学原料药注册标准编号：YBY62492025 包装规格：5kg/听 本次国药江苏威奇达的枸橼酸托法替布原料药获得上市申请批准，表明该原 料药符合国家相关药 ...

Summary of Guoyao Modern's Conference Call Company Overview - **Company**: Guoyao Modern - **Industry**: Pharmaceutical, specifically focusing on generic drugs and active pharmaceutical ingredients (APIs) Key Financial Performance - **Revenue**: 10.9 billion CNY, a decrease of 9.38% year-on-year [3] - **Net Profit**: 1.084 billion CNY, an increase of 56.6% year-on-year, with a five-year compound annual growth rate (CAGR) of 13.68% [3] - **Gross Margin**: Increased by 0.92 percentage points to 39.2% [3] - **Weighted ROE**: Reached 8.45%, an increase of 2.43 percentage points [3] - **Earnings per Share**: 0.81 CNY [3] - **Cash Flow**: Operating cash flow accounted for 20.63% of revenue, an increase of 6.38 percentage points [3] - **Debt Ratio**: Decreased to 23.22%, down 2.69 percentage points [4] Business Segment Performance Intermediate and API Business - **Revenue**: 5.198 billion CNY, an increase of 8.54% year-on-year [5] - **Core Products**: 85% of revenue from anti-infection products, with penicillin products growing by 20% and clavulanic acid series by 33%, while cephalosporin products declined by 32% [5] - **Export**: Nearly 80% of anti-infection products are for export [5] Formulation Business - **Revenue**: Decreased by over 20% [5] - **Profitability**: Maintained through cost control and changes in business model [5] - **Product Composition**: Anti-infection formulations account for 38%, cardiovascular and neurological formulations each account for 12% [5] Research and Development - **R&D Investment**: 600 million CNY, representing 6% of revenue [6] - **Projects**: 210 projects in progress, with 70% focused on new products [6] - **Focus Areas**: Emphasis on narcotics, anti-infection, cardiovascular, and oncology fields [6] Future Outlook - **2025 Revenue Projection**: Expected to reach 11.3 billion CNY, a growth of approximately 3% [7] - **Strategic Focus**: Digital empowerment, marketing reform, and optimization of industrial layout to enhance competitiveness [7] - **Chronic Disease Focus**: Concentration on cardiovascular, metabolic, and endocrine diseases under the backdrop of centralized procurement [10] Market Trends and Risks - **Raw Material Market**: Subject to global demand fluctuations, with potential price volatility due to supply-demand dynamics [8] - **Antibiotic Product Pricing**: Stable decline in prices observed in Q1, with expected demand reduction in summer months [9] - **Cost Management**: Strategies include capacity optimization, product structure adjustment, and strategic partnerships to mitigate cost impacts [11] Strategic Initiatives - **New Product Development**: Focus on high-value, technically challenging products, including first generic drugs and improved new drugs [10] - **Acquisition Plans**: Over 80 products under review, focusing on infection, cardiovascular, and neurological areas [12] - **Sales Strategy**: Emphasis on maintaining a stable sales expense ratio, currently around 10% [22] Conclusion Guoyao Modern is navigating a challenging pharmaceutical landscape with a strategic focus on enhancing profitability through R&D, cost management, and market adaptation. The company is poised for moderate growth in 2025 while addressing potential market risks and leveraging its strengths in high-demand therapeutic areas.

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of 1,083,622,881.88 CNY for the fiscal year 2024[4]. - The company achieved operating revenue of CNY 10.94 billion in 2024, a decrease of 9.38% compared to the previous year[21]. - Net profit attributable to shareholders reached CNY 1.08 billion, an increase of 56.62% year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1.04 billion, up 52.72% from the previous year[22]. - The total operating income decreased by 9.38% to approximately 10.94 billion RMB, while operating costs decreased by 10.73% to approximately 6.65 billion RMB[61]. - The company reported a net profit attributable to shareholders of 1.094 billion RMB, a year-on-year increase of 56.62%, with a return on equity increasing by 2.43 percentage points[59]. - The company reported a significant reduction in sales expenses due to a transformation in marketing models and better cost control[64]. - The overall gross margin improved to 39.24%, an increase of 0.91 percentage points year-on-year[64]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares (including tax), totaling 268,234,538.40 CNY based on a total share capital of 1,341,172,692 shares as of December 31, 2024[4]. - The total cash dividend amount for 2024 is CNY 402,351,807.60, which accounts for 37.13% of the net profit attributable to ordinary shareholders in the consolidated financial statements[184]. - The cumulative cash dividend amount over the last three accounting years is CNY 670,586,346.00, with a cash dividend ratio of 83.71% based on the average annual net profit of CNY 801,099,402.09[186]. Research and Development - The company invested CNY 675 million in R&D, accounting for 6.17% of operating revenue, an increase of 0.41 percentage points year-on-year[33]. - The total R&D expenditure amounted to ¥674,510,524.59, representing 6.17% of total revenue, with capitalized R&D accounting for 14.62%[75]. - The company launched 31 new research projects in 2024 and filed 11 provincial-level research applications, indicating a focus on innovation[34]. - The company applied for 39 patents and received 62 patents in 2024, including 34 invention patents[99]. - The company is committed to enhancing its research and development capabilities, as indicated by the significant investments in various therapeutic areas[111]. Market Position and Sales - The company ranked 13th in the "Top 100 Chinese Chemical Pharmaceutical Enterprises" list for 2023, reflecting its strong market position[39]. - Export sales revenue reached RMB 3.99 billion, a year-on-year growth of 25.95%, with the intermediates and APIs segment growing by 28.19%[34]. - The formulation segment achieved sales revenue of 5.451 billion RMB, a year-on-year decrease of 20.24%, accounting for 49.84% of total revenue, down 6.78 percentage points from the previous year[49]. - Sales revenue in the nervous system medication area decreased by 8.28% despite significant growth in the sales of certain products, with injection of fentanyl hydrochloride and minaprine tablets increasing by 22.64% and 33.58% respectively[49]. Risk Management and Compliance - There are no significant risks that materially affect the company's production and operations during the reporting period[6]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[6]. - The company has not violated decision-making procedures for providing guarantees to external parties[6]. - The company emphasizes compliance and risk control, aiming to enhance internal control and supervision mechanisms to support stable development[133]. Governance and Management - The company has established a comprehensive governance structure with clear responsibilities for the shareholders' meeting, board of directors, and supervisory board, ensuring effective decision-making and oversight[141]. - The board of directors consists of 9 members, including 7 external directors, and has established specialized committees to facilitate effective governance and decision-making[142]. - The company has implemented a performance-based evaluation mechanism for senior management, linking compensation to operational performance[187]. - The total pre-tax remuneration for the management team during the reporting period amounted to 934.32 million CNY[152]. Environmental Protection - The company has established a comprehensive environmental protection regulatory system across its key pollutant discharge units, enhancing management efficiency in environmental protection[196]. - All key pollutant discharge units are equipped with advanced environmental protection facilities, including internal wastewater treatment systems and air emission terminal treatment facilities, which are operating stably[196]. - The company has implemented a strict "three simultaneous" system for environmental protection in construction projects, ensuring compliance throughout the project lifecycle[197]. - The company has a monitoring system in place to ensure that pollutant emissions meet environmental standards consistently[197]. Strategic Initiatives - The company is committed to becoming an innovation-driven leader in the pharmaceutical industry, focusing on key therapeutic areas such as anti-infection and cardiovascular health[40]. - The company is actively adjusting its business layout and enhancing operational quality and efficiency in response to market changes and competitive pressures[46]. - The company plans to enhance its innovation capabilities in the pharmaceutical sector, aligning with government initiatives to promote modern industrial systems[86]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting a deal by Q1 2024[153].

上海现代制药股份有限公司 2024 年度报告摘要 公司代码：600420 公司简称：国药现代 上海现代制药股份有限公司 2024 年度报告摘要 上海现代制药股份有限公司 2024 年度报告摘要 第一节 重要提示 1、 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到 www.sse.com.cn 网站仔细阅读年度报告全文。 2、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 魏树源 | 工作原因 | 许继辉 | 4、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度实现合并归属于上市公司股东的 净利润 1,083,622,881. ...

证券代码：600420 证券简称：国药现代 公告编号：2025-025 证券代码：600420 证券简称：国药现代 公告编号：2025-025 上海现代制药股份有限公司 关于申请综合授信的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）于 2025 年 3 月 26 日召开第八 届董事会第二十次会议，审议通过了《关于申请综合授信的议案》，该议案尚需 提交公司 2024 年年度股东大会审议。 为满足公司日常生产经营及相关项目建设、投资等的资金需求，根据公司 2025 年度资金预算，公司拟向国有及商业股份制银行申请 1,357,020.00 万元综合 授信（含为子公司提供的担保授信），主要用于流动资金贷款、开立票据、保函、 信用证及并购贷款等融资业务。预计明细如下： | 序号 | 授信银行 | 授信额度（万元） | | --- | --- | --- | | 1 | 中国工商银行股份有限公司 | 45,000.00 | | 2 | 广发银行股份有限公司 | 19,900.00 | | ...

根据《上海证券交易所上市公司自律监管指引第 5 号—交易与关联交易》的 要求，通过查验国药集团财务有限公司（以下简称国药财务）的《营业执照》与 《金融许可证》等资料，并审阅了国药财务 2024 年度的财务报告以及风险指标 等必要信息，上海现代制药股份有限公司（以下简称国药现代）对国药财务的经 营资质、业务和风险状况进行了评估，具体情况报告如下： 一、国药财务基本情况 国药财务成立于2012年2月23日，是经中国银行业监督管理委员会批准成立 的非银行金融机构。 注册地址：北京市海淀区知春路20号 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 上海现代制药股份有限公司 关于国药集团财务有限公司的 2024 年度风险持续评估报告 经营范围：（一）吸收成员单位存款；（二）办理成员单位贷款；（三）办理 成员单位票据贴现；（四）办理成员单位资金结算与收付；（五）提供成员单位委 托贷款、债券承销、非融资性保函、财务顾问、信用鉴证及咨询代理业务；（六） 从事同业拆借；（七）办理成员单位票据承兑；（八）办理成员单位产品买方信贷； （九）从事固定收益类有价证券投资。 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-024 上海现代制药股份有限公司 关于拟与国药集团财务有限公司继续签署《金融服务协 议》暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 交易内容：上海现代制药股份有限公司（以下简称公司）拟与国药集团财 务有限公司（以下简称国药财务）继续签署《金融服务协议》，在协议有效期内， 公司在国药财务的日存款余额不超过人民币15亿元；贷款综合授信额度不超过人 民币25亿元。 关联董事回避：公司现任 6 名董事会成员中，关联董事许继辉先生、刘勇 先生、魏树源先生回避表决。本议案尚需提交公司 2024 年年度股东大会审议， 关联股东需回避表决。 一、关联交易概述 为了优化公司财务管理，提高资金使用效益，降低融资风险，公司拟与国药 财务继续签署《金融服务协议》，为公司提供存款、贷款、担保、结算等多种金 融服务。 1、关联方基本情况 公司名称：国药集团财务有限公司 注册地址：北京市海淀区知春路 20 号 注册资本：220,000.00 万人民币 经营 ...

上海现代制药股份有限公司 董事会审计与风险管理委员会对会计师事务所 2024 年度 履行监督职责情况的报告 上海现代制药股份有限公司（以下简称公司）于 2024 年 3 月 28 日召开第 八届董事会第十二次会议、第八届监事会第七次会议审议通过了《关于续聘 2024 年度会计师事务所的议案》，拟续聘天健会计师事务所（特殊普通合伙） （以下简称天健事务所）为公司 2024 年度财务报告和内部控制审计机构，该议 案于 2024 年 5 月 28 日经公司 2023 年年度股东大会审议通过。 根据《国有企业、上市公司选聘会计师事务所管理办法》的有关规定，公 司董事会审计与风险管理委员会勤勉尽责，恪尽职守，认真履职，对天健事务 所 2024 年度的审计工作情况履行了监督职责。具体情况报告如下： 4、与会计师事务所沟通及对 2024 年财务报告的审议情况 审计与风险管理委员会对天健事务所的独立性、专业资质、业务能力、投 资者保护能力、诚信状况、过往审计工作情况及其执业质量等进行了核查和评 价，认为其具备为公司提供审计工作的独立性、资质和专业能力，能够满足公 司审计工作的要求。 2、向董事会提出聘请会计师事务所的建议情况 ...